RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Cash And Cash Equivalents : $0.01 Mil (As of Sep. 2023)

View and export this data going back to 2009. Start your Free Trial

What is RespireRx Pharmaceuticals Cash And Cash Equivalents?

RespireRx Pharmaceuticals's quarterly cash and cash equivalents increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.01 Mil) but then stayed the same from Jun. 2023 ($0.01 Mil) to Sep. 2023 ($0.01 Mil).

RespireRx Pharmaceuticals's annual cash and cash equivalents stayed the same from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil).

RespireRx Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for RespireRx Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RespireRx Pharmaceuticals Cash And Cash Equivalents Chart

RespireRx Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.03

0.02

RespireRx Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial															-	-	-	0.01	0.01

RespireRx Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

RespireRx Pharmaceuticals (OTCPK:RSPI) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

RespireRx Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of RespireRx Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

RespireRx Pharmaceuticals (RespireRx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RespireRx Pharmaceuticals Inc (OTCPK:RSPI) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452

Website

http://www.respirerx.com

RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. The company also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.

Executives

David Dickason	officer: SVP of Pre-Clinical Prod. Dev.	126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Timothy L. Jones	director, officer: CEO and President	126 VALLEY ROAD, SUITE C, GLEN ROCK NJ 07452
Manuso James S J	director, officer: President & CEO	5130 ROUTE 212, WILLOW NY 12495
Katie Macfarlane	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Purcell Richard David Jr.	officer: SVP - Research & Deleopment	65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
James Sapirstein	director	1517 SAN JACINTO, HOUSTON TX 77002
Marc M Radin	officer: Controller	33 FRANKLIN PLACE, GLEN ROCK NJ 07452
Robert N Weingarten	director, officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
Aurora Capital Llc	other: Member of a 10% owner group	354 WIDOW GAVITS ROAD, PO BOX 1167, BRIDGEHAMPTON, NY 11932-1167
Aurora Capital Corp	other: Member of 10% owner group
Jeff Eliot Margolis	director, officer: Vice President, Sec. & Treas., other: Member of 10% owner group	C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Steven Chizzik	other: Member of 10% owner group	C/O THE VERRAZANO GROUP, LLC, 2204 MORRIS AVENUE, SUITE 203A, UNION NJ 07083
Arnold Lippa	director, officer: Chairman, CEO and President, other: Member of 10% owner group	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
T. Morgen Capital Llc	other: Member of 10% owner group	C/O AURORA CAPITAL LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
Kenneth M Cohen	other: Member of 10% owner group	12750 HIGH BLUFF DRIVE, SUITE 310, SAN DIEGO CA 92130